EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms

Bence Ferencz, Klára Török, Orsolya Pipek, János Fillinger, Kristóf Csende, András Lantos, Radoslava Černeková, Marcel Mitták, Jozef Škarda, Patricie Delongová, Evelyn Megyesfalvi, Karin Schelch und 10 weitere

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03704-7 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Bence Ferencz und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary. Hauptthemen laut MEDLINE: Lung Neoplasms, Hepatitis A Virus Cellular Receptor 2, Immunotherapy, Neuroendocrine Tumors. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, Magyar Tudományos Akadémia, Austrian Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Advancements in immunotherapeutic approaches only had a modest impact on the therapy of lung neuroendocrine neoplasms (LNENs). Our multicenter study aimed to investigate the expression patterns of novel immunotherapy targets in intermediate- and high-grade LNENs.

Methods

The expressions of V-domain Ig suppressor of T cell activation (VISTA), OX40L, Glucocorticoid-induced TNF receptor (GITR), and T cell immunoglobulin and mucin domain 3 (TIM3) proteins were measured by immunohistochemistry in surgically resected tumor samples of 26 atypical carcinoid (AC), 49 large cell neuroendocrine lung cancer (LCNEC), and 66 small cell lung cancer (SCLC) patients. Tumor and immune cells were separately scored.

Results

Tumor cell TIM3 expression was the highest in ACs ( p < 0.001), whereas elevated tumor cell GITR levels were characteristic for both ACs and SCLCs ( p < 0.001 and p = 0.011, respectively). OX40L expression of tumor cells was considerably lower in ACs (vs. SCLCs; p < 0.001). Tumor cell VISTA expression was consistently low in LNENs, with no significant differences across histological subtypes. ACs were the least immunogenic tumors concerning immune cell abundance ( p < 0.001). Immune cell VISTA and GITR expressions were also significantly lower in these intermediate-grade malignancies than in SCLCs or in LCNECs. Immune cell TIM3 and GITR expressions were associated with borderline prognostic significance in our multivariate model ( p = 0.057 and p = 0.071, respectively).

Conclusions

LNEN subtypes have characteristic and widely divergent VISTA, OX40L, GITR, and TIM3 protein expressions. By shedding light on the different expression patterns of these immunotherapy targets, the current multicenter study provides support for the future implementation of novel immunotherapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHepatitis A Virus Cellular Receptor 2ImmunotherapyNeuroendocrine TumorsGlucocorticoid-Induced TNFR-Related ProteinBiomarkers, TumorHumansMaleFemaleMiddle AgedAgedB7 AntigensAdultNeoplasm GradingOX40 LigandPrognosisAged, 80 and over

Stichwörter der Autor:innen

Immune phenotypeImmunohistochemistryImmunotherapy targetLung neuroendocrine neoplasm

Substanzen

Hepatitis A Virus Cellular Receptor 2HAVCR2 protein, humanGlucocorticoid-Induced TNFR-Related ProteinBiomarkers, TumorB7 AntigensVSIR protein, humanOX40 LigandTNFRSF18 protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary.
  • National Koranyi Institute of Pulmonology, Budapest, Hungary.
  • Department of Physics of Complex Systems, Eotvos Lorand University, Budapest, Hungary.
  • Department of Pulmonary Diseases and Tuberculosis, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Surgical Clinic, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Medical Faculty, Institute of Clinical and Molecular Pathology, Palacky University Olomouc, Olomouc, Czech Republic.

Förderung

  • Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
  • Magyar Tudományos Akadémia
  • Austrian Science Fund
  • International Association for the Study of Lung Cancer
  • Austrian Science Fund FWF
  • Semmelweis Egyetem
  • Innovációs és Technológiai Minisztérium
  • Hochschuljubiläumsstiftung der Stadt Wien

Zitieren

APA

Ferencz, B., Török, K., Pipek, O., Fillinger, J., Csende, K., Lantos, A., Černeková, R., Mitták, M., Škarda, J., Delongová, P., Megyesfalvi, E., Schelch, K., Lang, C., Solta, A., Boettiger, K., Brcic, L., Lindenmann, J., Rényi-Vámos, F., Aigner, C., …, & Döme, B. (2024). Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03704-7

Vancouver

Ferencz B, Török K, Pipek O, Fillinger J, Csende K, Lantos A, et al. Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03704-7

BibTeX
@article{Ferencz2024,
  author = {Ferencz, Bence and Török, Klára and Pipek, Orsolya and Fillinger, János and Csende, Kristóf and Lantos, András and Černeková, Radoslava and Mitták, Marcel and Škarda, Jozef and Delongová, Patricie and Megyesfalvi, Evelyn and Schelch, Karin and Lang, Christian and Solta, Anna and Boettiger, Kristiina and Brcic, Luka and Lindenmann, Jörg and Rényi-Vámos, Ferenc and Aigner, Clemens and Berta, Judit and Megyesfalvi, Zsolt and Döme, Balázs},
  title = {Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03704-7}
}
Kostenlos starten →